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SELECTION OF THE MONTH 
Big Title: PNPLA3 increases risk of death in alcoholic hepatitis 
 
Small title: Carvedilol increases survival of decompensated cirrhosis patients 
 
LIVER INJURIES 
Thymic MAP3K14 and liver homeostasis, deciphering chemotherapy-related 
liver injuries (CALI) 
Breakdown of liver immune privilege can develop in chronic liver disease; however, 
the role of adaptive immunity in liver injury is poorly defined. Here Shen et al. 
investigated the role of mitogen-activated protein kinase kinase kinase 14 (MAP3K14, 
also known as NIK) because it is involved in NF-κB activation in immune cells and 
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because of its role in maintaining liver homeostasis is unknown. For this, they deleted 
MAP3K14 systemically or conditionally in mice. They reveal that thymic MAP3K14 
suppresses development of autoreactive T cells against liver antigens, and MAP3K14 
deficiency in the thymus results in CD4+ T cell-orchestrated autoimmune hepatitis and 
liver fibrosis. Thus, thymic MAP3K14 is indispensable for the maintenance of liver 
immune privilege and liver homeostasis. 
CALI increase the risk of liver resection and may prejudice further surgery and 
chemotherapy. No data regarding reversibility of CALI are available. Vigano et al. 
retrospectively analyzed the reversibility of CALI in patients undergoing liver resection 
for colorectal metastases. They found that CALI persists for a long time after 
chemotherapy. The sinusoidal obstruction syndrome and nodular regenerative 
hyperplasia regress only after nine months without chemotherapy, whereas 
steatosis and steatohepatitis persist. 
 
CHOLANGIOCARCINOMA (CCA) 
SOX17 in CCA 
CCA is a biliary malignancy associated with epigenetic abnormalities, such as 
hypermethylation of the promoter of SOX17 (for Sex Determining Region Y [SRY]-box 
17). SOX19 is one of the 19 genes of the gene family of SRY-boxes (HUGO Gene 
Name nomenclature; http://www.genenames.org) that encode transcription factors 
involved in the regulation of embryonic development and in the determination of the 
cell fate. The transcription factor encoded by SOX17 binds to DNA sequences 5'-
AACAAT-'3 or 5'-AACAAAG-3'. It modulates transcriptional regulation via WNT3A, 
inhibits Wnt signaling and promotes degradation of activated CTNNB1. Here, Merino-
Azpitarte et al. investigated the role of SOX17 in cholangiocyte differentiation and 
cholangiocarcinogenesis. For this, they studied SOX17 expression/function along the 
differentiation of human induced pluripotent stem cells into cholangiocytes, in the 
dedifferentiation process of normal human cholangiocytes in culture and in 
cholangiocarcinogenesis. They show that SOX17 regulates the differentiation and 
maintenance of the biliary phenotype and functions as a tumor suppressor for 
CCA, suggesting a potential prognostic marker and a promising therapeutic 
target. 
 
HEPATOCELLULAR CARCINOMA (HCC) 
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Early events determine the outcome of successfully treated HCC in patients with 
HCV-related cirrhosis 
Here, Cabibbo et al. aimed to estimate the impact on 5-year overall survival of early 
(occurring within 12 months after complete radiological response) time-dependent 
events (HCC recurrence or hepatic decompensation) in a large cohort of successfully 
treated HCC patients with HCV-related cirrhosis. They reveal that survival in HCV-
infected cirrhotic patients with successfully treated HCC is mainly influenced by 
early hepatic decompensation. These findings suggest that the use of direct antiviral 
agents may improve survival of patients with HCV-related cirrhosis and successfully 
treated HCC; this hypothesis deserves to be addressed in future studies. 
 
GENETICS IN LIVER DISEASE 
Genetic determinants to drug-induced liver injury (DILI) by minocycline, NASH, 
and alcoholic hepatitis-associated mortality 
Factors predisposing to minocycline-induced hepatotoxicity are unknown. Fontana 
et al. performed genome-wide genotyping in a well characterized cohort. Most patients 
were women and 90% had positive ANA. A significant association was noted 
between a HLA class I histocompatibility antigen, B-35 alpha chain (HLA-
B*35:02) and risk for minocycline-DILI (16% carrier frequency in DILI cases 
compared to 0.6% in population controls). HLA-B*35:02 carriers had similar presenting 
features and outcomes compared to noncarriers. In silico modeling studies supported 
the hypothesis that direct binding of minocycline to this novel HLA risk allele might be 
an important initiating event in minocycline-DILI. If confirmed in other cohorts, this HLA 
allele may prove to be a useful diagnostic marker of minocycline DILI. 
Carriers of a variant in the transmembrane 6 superfamily member 2 (TM6SF2) gene 
that results in a E167K substitution in the encoded protein, have increased risk of 
NASH. Interestingly, these subjects lack hypertriglyceridemia and have lower risk of 
cardiovascular disease. In animals, phosphatidylcholine (PC) deficiency results in a 
similar phenotype. Luukkonen et al. studied the effect of the TM6SF2 E167K on these 
lipids in human livers and cultured hepatocytes. Patients with TM6SF2 EK/KK had 
higher liver triglycerides but lower PCs. Also, incorporation of PUFA into triglycerides 
and PCs in TM6SF2 knockdown hepatocytes was decreased. As expected, hepatic 
expression of TM6SF2 was decreased in variant carriers, and was coexpressed with 
genes regulated by PUFAs. This interesting study demonstrates that hepatic lipid 
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synthesis from PUFAs is impaired and could contribute to deficiency in PCs and 
increased intrahepatic triglycerides in TM6SF2 E167K variant carriers. 
Carriage of an allele in PNPLA3 (rs738409[G], encoding I148M) is associated with an 
increased risk of developing alcohol-related cirrhosis. In an important study in this issue 
of the Journal, Atkinson et al. assessed whether carriage of rs738409[G] has an 
additional detrimental effect on survival in patients with alcoholic hepatitis, the most 
deadly form of ALD. Almost 900 patients from the STOPAH trial and 2,000 alcohol 
dependent controls were included. The frequency of rs738409[G] was significantly 
higher in cases than controls (29% vs. 19%; p=2.15x10-15). There was no association 
between rs738409[G] and 28-day mortality. However, mortality in the period day 90-
450 was higher in survivors who subsequently resumed drinking and individuals 
homozygous for rs738409[G] (HR 1.69, 95% CI 1.02-2.81, p=0.04). This study 
suggests that homozygosity for rs738409[G] in PNPLA3 confers significant additional 
risk of medium-term mortality in patients with severe alcoholic hepatitis.  
 
HEPATITIS C VIRUS (HCV) INFECTION  
DAA treatment in prior HCC patients - the Veterans Affairs experience, curing 
HCV in HIV co-infection, lower than expected increase in DAA prescriptions 
The effectiveness of direct acting antivirals (DAAs) in patients with a history of HCV-
induced HCC is largely unknown as these patients were systematically excluded from 
prospective controlled trials. The objective of the study by Beste et al. was to describe 
the characteristics of HCC patients who receive DAA-based antiviral treatment and to 
report the rates and predictors of SVR by using the Veterans Affairs Corporate Data 
Warehouse which includes the largest cohorts of HCV and HCC patients in the US. Of 
17,487 HCV treatment recipients, 624 (3.6%) had prior HCC, and these patients were 
divided into those who were treated with liver transplantation after HCC diagnosis, and 
those treated with other modalities prior to antiviral therapy. After adjustment for 
confounders, the presence of HCC was associated with lower likelihood of SVR 
(74.5%) when DAA treatment was applied prior to liver transplantation as compared to 
those patients with HCC receiving DAA therapy after liver transplantation (93.4%) but 
also as compared the overall non-HCC group (91.9%). The findings suggest that 
patients with HCV-induced HCC listed for transplantation may benefit from 
deferring HCV treatment until after transplantation. Further studies should explore 
the impact of HCV treatment on subsequent HCC behavior. 
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With the advent of potent DAA combination regimens for the first time similar SVR 
rates were achieved in the formerly named difficult-to-cure HIV-HCV-co-infected, and 
HCV-mono-infected patients in clinical trials. However, participants in clinical trials are 
not always fully representative of patients followed in “real-life”. Piroth, Wittkop et al. 
report the efficacy and safety of all-oral DAA-based regimens according to the 
concomitant antiretroviral regimen in HIV-HCV co-infected patients enrolled the French 
nationwide ANRS CO13 HEPAVIH observational cohort. A high overall SVR12 of 
93.5% was observed in the real-life setting, and neither the HCV type nor fibrosis 
status influenced SVR rates. This study confirms the impressive safety and efficacy 
of DAA regimens in a large nationwide cohort of HIV-HCV co-infected patients. 
In Germany, in contrast to most other European countries, all patients with chronic 
HCV infection are eligible for treatment, regardless of the clinical stage of liver 
impairment. The aims of the study by Zimmermann et al. were to determine the monthly 
number of HCV antiviral treatments prescribed for HCV patients with statutory health 
insurance in Germany between January 2010 and December 2015, but also how DAA 
treatment options influenced the treatment rates. Given an estimated number of 
160,000 patients with diagnosed HCV infection in Germany, a much lower than 
expected increase of monthly prescriptions of HCV treatment have been 
observed since 2010. Limited access to specialized health care, ambiguities in the 
reimbursement system, but also a smaller than estimated pool of HCV infected patients 
may explain these results. This study provides important information how to improve 
linkage to care in order achieve the goal of eliminating HCV infection just by antiviral 
treatment.   
(Thomas: Would suggest to show the graphical abstract figure for this 
contribution; RM: Agree) 
 
CIRRHOSIS 
Carvedilol administration increases the survival of cirrhotic patients with ascites 
Non-selective beta-blockers (NSBB) have been the mainstay of treatment of patients 
with portal hypertension for over 3 decades but their use in patients with refractory 
ascites has been under scrutiny. Carvedilol is also an NSBB but in addition has alpha-
1 receptor agonist properties and has been shown in many studies to effectively reduce 
portal pressure. Sinha et al. performed an extremely important study in cirrhotic 
patients with ascites treated with carvedilol and compared this with a propensity score 
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matched patient population. The study shows that the carvedilol treated patients 
had a staggeringly low mortality of 2% compared with the control group of 24% 
(p<0.0001). These data would change practice if they were confirmed in randomized 
studies.  
 
CHOLESTASIS AND RENAL DYSFUNCTION 
Nor Urosdeoxycholic (NorURSO) acid is a novel strategy to treat cholestasis 
associated nephropathy 
The occurrence of renal dysfunction on the background of cholestasis, referred to as 
cholemic nephropathy is associated with poor clinical outcomes. NorUDCA is a bile 
acid derivative that allows excretion of toxic bile acids through alternative excretory 
routes. Krones et al. administered NorUDCA to bile duct ligated rats and show 
that the animals administered the drug had significantly better renal function, 
reduced urinary NGAL and preserved renal histology compared with untreated 
controls. The data provide a novel approach to the treatment of cholemic 
nephropathy, which can be translated readily into the clinic as NorUDCA is already a 
Phase 2 compound. 
 
CELL TRANSPLANTATION 
Mesenchymal stromal cell (MSC) infusion for tolerance induction post liver 
transplantation 
MSCs are multipotent progenitors within the bone marrow that can differentiate into 
multiple cell types. They modulate inflammatory responses and have the ability to 
potentially induce tolerance. Detry et al. performed a Phase I/II clinical trial infusing 
MSCs into patients soon after undergoing liver transplantation. They show for 
the first time that this approach is safe and can be performed without increasing 
the risk of infection or development of cancer. Although the data did not show that 
this induces tolerance, it provides important safety data to further develop this or a 
similar cellular approach for patients undergoing liver transplantation. 
 
